212 related articles for article (PubMed ID: 25053806)
1. Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer.
Gelman IH; Peresie J; Eng KH; Foster BA
Mol Cancer Res; 2014 Oct; 12(10):1470-9. PubMed ID: 25053806
[TBL] [Abstract][Full Text] [Related]
2. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
3. Systemic Ablation of
Pulliam TL; Awad D; Han JJ; Murray MM; Ackroyd JJ; Goli P; Oakhill JS; Scott JW; Ittmann MM; Frigo DE
Cells; 2022 Jun; 11(12):. PubMed ID: 35741020
[TBL] [Abstract][Full Text] [Related]
4. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
[TBL] [Abstract][Full Text] [Related]
5. Differential transformation capacity of Src family kinases during the initiation of prostate cancer.
Cai H; Smith DA; Memarzadeh S; Lowell CA; Cooper JA; Witte ON
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6579-84. PubMed ID: 21464326
[TBL] [Abstract][Full Text] [Related]
6. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM
Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980
[TBL] [Abstract][Full Text] [Related]
7. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
8. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
9. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.
Littlepage LE; Sternlicht MD; Rougier N; Phillips J; Gallo E; Yu Y; Williams K; Brenot A; Gordon JI; Werb Z
Cancer Res; 2010 Mar; 70(6):2224-34. PubMed ID: 20215503
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
12. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
Yang JC; Ok JH; Busby JE; Borowsky AD; Kung HJ; Evans CP
Cancer Res; 2009 Jan; 69(1):151-60. PubMed ID: 19117998
[TBL] [Abstract][Full Text] [Related]
13. The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate.
Tien JC; Liao L; Liu Y; Liu Z; Lee DK; Wang F; Xu J
Int J Biol Sci; 2014; 10(10):1116-27. PubMed ID: 25332686
[TBL] [Abstract][Full Text] [Related]
14. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
Tatarov O; Mitchell TJ; Seywright M; Leung HY; Brunton VG; Edwards J
Clin Cancer Res; 2009 May; 15(10):3540-9. PubMed ID: 19447874
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
16. Src controls castration recurrence of CWR22 prostate cancer xenografts.
Su B; Gillard B; Gao L; Eng KH; Gelman IH
Cancer Med; 2013 Dec; 2(6):784-92. PubMed ID: 24403252
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
18. The role of SRC-1 in murine prostate cancinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression.
Tien JC; Zhou S; Xu J
Int J Biol Sci; 2009; 5(3):256-64. PubMed ID: 19305643
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
20. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
